Payment overview · 2025
General Payments
$1,457.65
22 reported records · 7 companies
Healthcare provider profile · identity verified
Chung The Bui, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WESTMINSTER, CA · NPI 1427143072
Verified facts
What the public records show
CMS Open Payments records show Chung The Bui, M.D. received $1,457.65 in general payments during 2025 across 22 reported records.
Lilly USA, LLC accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Prolia, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $355.93 | 24.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $295.25 | 20.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $273.74 | 18.8% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $253.63 | 17.4% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $144.10 | 9.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $111.96 | 7.7% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.04 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,282.65 | 21 |
| Consulting Fee | $175.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $353.68 | 7 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $253.63 | 7 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $175.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $144.10 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $134.24 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $123.50 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $120.25 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $114.21 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 249 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
249 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
249 | 56 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 516 | 154 |
| Losartan Potassium | Losartan Potassium | 334 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 306 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 279 | 89 |
| Jardiance | Empagliflozin | 249 | 56 |
| Metformin Hcl Er | Metformin Hcl | 237 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 216 | 62 |
| Gabapentin | Gabapentin | 209 | 88 |
| Tamsulosin Hcl | Tamsulosin Hcl | 203 | 53 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 200 | 67 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 148 | 65 |
| Tradjenta | Linagliptin | 125 | 27 |
| Metformin Hcl | Metformin Hcl | 115 | 31 |
| Vascepa | Icosapent Ethyl | 103 | 26 |
| Famotidine | Famotidine | 100 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 32 |
| Linzess | Linaclotide | 96 | 27 |
| Alendronate Sodium | Alendronate Sodium | 95 | 30 |
| Finasteride | Finasteride | 89 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 35 |
| Farxiga | Dapagliflozin Propanediol | 74 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 69 | 32 |
| Creon | Lipase/Protease/Amylase | 64 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 64 | 19 |
| Celecoxib | Celecoxib | 59 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 18 |
| Zenpep | Lipase/Protease/Amylase | 59 | 15 |
| Mirtazapine | Mirtazapine | 54 | 20 |
| Dutasteride | Dutasteride | 53 | 15 |
| Azithromycin | Azithromycin | 51 | 35 |
| Sildenafil Citrate | Sildenafil Citrate | 49 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 14 |
| Montelukast Sodium | Montelukast Sodium | 46 | 12 |
| Allopurinol | Allopurinol | 41 | 13 |
| Omeprazole | Omeprazole | 41 | 19 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 38 | 26 |
| Naproxen | Naproxen | 37 | 23 |
| Loperamide | Loperamide Hcl | 33 | 27 |
| Procto-Med Hc | Hydrocortisone | 31 | 16 |
| Amoxicillin | Amoxicillin | 30 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 26 |
| Baclofen | Baclofen | 30 | 13 |
| Cromolyn Sodium | Cromolyn Sodium | 30 | 18 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 30 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 17 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Prednisone | Prednisone | 23 | 20 |
| Pregabalin | Pregabalin | 23 | suppressed |
| Proctozone-Hc | Hydrocortisone | 23 | 11 |
| Restasis | Cyclosporine | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | 16 |
| Carvedilol | Carvedilol | 21 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | 11 |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Entecavir | Entecavir | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,457.65 · 22 records | Lilly USA, LLC | AIRSUPRA, BREZTRI, EVENITY, JARDIANCE, Kerendia, MOUNJARO, PROLIA, TEZSPIRE, VOQUEZNA, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error